Guillermo Videla Richardson

Dr. Guillermo Videla Richardson

Laboratorio de Investigación Aplicada en Neurociencias (LIAN), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI), Belén de Escobar, Provincia de Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Stem Cell Research
Verified
Journal Article
Open access
CGCarolina Paola García
Carolina Paola García
GRGuillermo Videla Richardson
Guillermo Videla Richardson
LRLeonardo Romorini
Leonardo Romorini
SMSantiago Gabriel Miriuka
Santiago Gabriel Miriuka
GSGustavo Emilio Sevlever
Gustavo Emilio Sevlever
MSMaría Elida Scassa
María Elida Scassa
Embryonic stem cells (ESCs) need to maintain their genomic integrity in response to DNA damage to safeguard the integrity of the organism. DNA double strand breaks (DSBs) are one of the most lethal forms of DNA damage and, if not repaired correctly, they can lead to cell death, genomic instability and cancer. How human ESCs (hESCs) maintain genomic integrity in response to agents that cause DSBs is relatively unclear. In the present study we aim to determine the hESC response to the DSB inducing agent camptothecin (CPT). We find that hESCs are hypersensitive to CPT, as evidenced by high levels of apoptosis. CPT treatment leads to DNA-damage sensor kinase (ATM and DNA-PKcs) phosphorylation on serine 1981 and serine 2056, respectively. Activation of ATM and DNA-PKcs was followed by histone H2AX phosphorylation on Ser 139, a sensitive reporter of DNA damage. Nuclear accumulation and ATM-dependent phosphorylation of p53 on serine 15 were also observed. Remarkably, hESC viability was further decreased when ATM or DNA-PKcs kinase activity was impaired by the use of specific inhibitors. The hypersensitivity to CPT treatment was markedly reduced by blocking p53 translocation to mitochondria with pifithrin-μ. Importantly, programmed cell death was achieved in the absence of the cyclin dependent kinase inhibitor, p21(Waf1), a bona fide p53 target gene. Conversely, differentiated hESCs were no longer highly sensitive to CPT. This attenuated apoptotic response was accompanied by changes in cell cycle profile and by the presence of p21(Waf1). The results presented here suggest that p53 has a key involvement in preventing the propagation of damaged hESCs when genome is threatened. As a whole, our findings support the concept that the phenomenon of apoptosis is a prominent player in normal embryonic development.

19 May 2015 in Brain Pathology
Verified
Journal Article
Open access
PDF file
GRGuillermo Videla Richardson
Guillermo Videla Richardson
CGCarolina Paola Garcia
Carolina Paola Garcia
ARAlejandro Roisman
Alejandro Roisman
ISIrma Slavutsky
Irma Slavutsky
DEDamián Darío Fernandez Espinosa
Damián Darío Fernandez Espinosa
GSGustavo Emilio Sevlever
Gustavo Emilio Sevlever
Although BMP4‐induced differentiation of glioma stem cells (GSCs) is well recognized, details of the cellular responses triggered by this morphogen are still poorly defined. In this study, we established several GSC‐enriched cell lines (GSC‐ECLs) from high‐grade gliomas. The expansion of these cells as adherent monolayers, and not as floating neurospheres, enabled a thorough study of the phenotypic changes that occurred during their differentiation. Herein, we evaluated GSC‐ECLs’ behavior toward differentiating conditions by depriving them of growth factors and/or by adding BMP4 at different concentrations. After analyzing cellular morphology, proliferation and lineage marker expression, we determined that GSC‐ECLs have distinct preferences in lineage choice, where some of them showed an astrocyte fate commitment and others a neuronal one. We found that this election seems to be dictated by the expression pattern of BMP signaling components present in each GSC‐ECL. Additionally, treatment of GSC‐ECLs with the BMP antagonist, Noggin, also led to evident phenotypic changes. Interestingly, under certain conditions, some GSC‐ECLs adopted an unexpected smooth muscle‐like phenotype. As a whole, our findings illustrate the wide differentiation potential of GSCs, highlighting their molecular complexity and paving a way to facilitate personalized differentiating therapies.

23 May 2019 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
OHOlivia Morris Hanon
Olivia Morris Hanon
MMMariela Claudia Marazita
Mariela Claudia Marazita
LRLeonardo Romorini
Leonardo Romorini
LILuciana Isaja
Luciana Isaja
DFDamián Darío Fernandez-Espinosa
Damián Darío Fernandez-Espinosa
GRGuillermo Videla Richardson
Guillermo Videla Richardson

22 February 2023 in Viruses
Verified
Journal Article
Open access
PDF file
MFMatias Garcia Fallit
Matias Garcia Fallit
MPMatias Luis Pidre
Matias Luis Pidre
AAAntonela S. Asad
Antonela S. Asad
JAJorge Armando Peña Agudelo
Jorge Armando Peña Agudelo
MVMariana Belén Vera
Mariana Belén Vera
MCMarianela Candolfi
Marianela Candolfi
We aimed to assess the potential of baculoviral vectors (BV) for brain cancer gene therapy. We compared them with adenoviral vectors (AdV), which are used in neuro-oncology, but for which there is pre-existing immunity. We constructed BVs and AdVs encoding fluorescent reporter proteins and evaluated their transduction efficiency in glioma cells and astrocytes. Naïve and glioma-bearing mice were intracranially injected with BVs to assess transduction and neuropathology. Transgene expression was also assessed in the brain of BV-preimmunized mice. While the expression of BVs was weaker than AdVs in murine and human glioma cell lines, BV-mediated transgene expression in patient-derived glioma cells was similar to AdV-mediated transduction and showed strong correlation with clathrin expression, a protein that interacts with the baculovirus glycoprotein GP64, mediating BV endocytosis. BVs efficiently transduced normal and neoplastic astrocytes in vivo, without apparent neurotoxicity. BV-mediated transgene expression was stable for at least 21 days in the brain of naïve mice, but it was significantly reduced after 7 days in mice systemically preimmunized with BVs. Our findings indicate that BVs efficiently transduce glioma cells and astrocytes without apparent neurotoxicity. Since humans do not present pre-existing immunity against BVs, these vectors may constitute a valuable tool for the delivery of therapeutic genes into the brain.

1 July 2017 in Neoplasia
Verified
Journal Article
Open access
OHOlivia Morris Hanon
Olivia Morris Hanon
VFVerónica Alejandra Furmento
Verónica Alejandra Furmento
MRMaría Soledad Rodríguez-Varela
María Soledad Rodríguez-Varela
SMSofía Mucci
Sofía Mucci
DFDamián Darío Fernandez-Espinosa
Damián Darío Fernandez-Espinosa
GRGuillermo Videla Richardson
Guillermo Videla Richardson
High-grade gliomas are the most prevalent and lethal primary brain tumors. They display a hierarchical arrangement with a population of self-renewing and highly tumorigenic cells called cancer stem cells. These cells are thought to be responsible for tumor recurrence, which make them main candidates for targeted therapies. Unbridled cell cycle progression may explain the selective sensitivity of some cancer cells to treatments. The members of the Cip/Kip family p21Cip1 and p27Kip1 were initially considered as tumor suppressors based on their ability to block proliferation. However, they are currently looked at as proteins with dual roles in cancer: one as tumor suppressor and the other as oncogene. Therefore, the aim of this study was to determine the functions of these cell cycle inhibitors in five patient-derived glioma stem cell-enriched cell lines. We found that these proteins are functional in glioma stem cells. They negatively regulate cell cycle progression both in unstressed conditions and in response to genotoxic stress. In addition, p27Kip1 is upregulated in nutrient-restricted and differentiating cells, suggesting that this Cip/Kip is a mediator of antimitogenic signals in glioma cells. Importantly, the lack of these proteins impairs cell cycle halt in response to genotoxic agents, rendering cells more vulnerable to DNA damage. For these reasons, these proteins may operate both as tumor suppressors, limiting cell proliferation, and as oncogenes, conferring cell resistance to DNA damage. Thus, deepening our knowledge on the biological functions of these Cip/Kips may shed light on how some cancer cells develop drug resistance.

13 June 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
NGNazareno Gonzalez
Nazareno Gonzalez
MKMelanie de Investigaciones Biomédicas Perez Küper
Melanie de Investigaciones Biomédicas Perez Küper
MFMatias Garcia Fallit
Matias Garcia Fallit
JAJorge Armando Peña Agudelo
Jorge Armando Peña Agudelo
ACAlejandro Javier Nicola Candia
Alejandro Javier Nicola Candia
MCMarianela Candolfi
Marianela Candolfi
Background: Glioblastoma (GBM) remains a significant challenge in oncology due to its resistance to standard treatments including temozolomide. This study aimed to develop and validate an integrated model for predicting GBM sensitivity to alternative chemotherapeutics and identifying new drugs and combinations with therapeutic potential. Research Design and Methods: We analyzed drug sensitivity data for 272 compounds from CancerRxTissue and employed in silico algorithms to assess blood-brain barrier permeability. The model was used to predict GBM sensitivity to various drugs, which was then validated using GBM cellular models. Alternative drugs targeting overexpressed and negative prognostic biomarkers in GBM were experimentally validated. Results: The model predicted that GBM is more sensitive to Etoposide and Cisplatin compared to Temozolomide, which was confirmed by experimental validation in GBM cells. We also identified novel drugs with high predicted sensitivity in GBM. Daporinad, a NAMPT inhibitor that permeates the blood-brain barrier was selected for further preclinical evaluation. This evaluation supported the in silico predictions of high potential efficacy and safety in GBM. Conclusions: Our findings using different cellular models suggest that this computational prediction model could constitute a valuable tool for drug repurposing in GBM and potentially in other tumors, which could accelerate the development of more effective cancer treatments.